Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

89bio, Inc. (ETNB)

20.45   0.46 (2.3%) 06-06 16:00
Open: 19.97 Pre. Close: 19.99
High: 20.85 Low: 19.28
Volume: 1,473,247 Market Cap: 1,490(M)

Technical analysis

as of: 2023-06-06 3:49:06 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 24.35     One year: 28.44
Support: Support1: 17.5    Support2: 15.44
Resistance: Resistance1: 20.85    Resistance2: 24.35
Pivot: 17.84
Moving Average: MA(5): 19.27     MA(20): 17.85
MA(100): 14.8     MA(250): 9.84
MACD: MACD(12,26): 0.8     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 92.5     %D(3): 91.1
RSI: RSI(14): 71
52-week: High: 20.85  Low: 2.91
Average Vol(K): 3-Month: 2,301 (K)  10-Days: 1,255 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ETNB ] has closed above the upper band by 3.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 30.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.13 - 20.2 20.2 - 20.27
Low: 18.62 - 18.7 18.7 - 18.78
Close: 19.85 - 19.97 19.97 - 20.09

Company Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Headline News

Tue, 06 Jun 2023
89bio Inc (ETNB) Stock Is Higher By 16.84% This Week: Buy, Hold, or Sell? - InvestorsObserver

Tue, 06 Jun 2023
89bio, Inc. (NASDAQ:ETNB) Director Edward Morrow Atkinson III ... - Defense World

Tue, 06 Jun 2023
89bio, Inc. (NASDAQ:ETNB) Receives Consensus Rating of "Buy ... - MarketBeat

Mon, 29 May 2023
Validea's Top 5 Health Care Stocks Based On Warren Buffett - 5/29 ... - Nasdaq

Sun, 28 May 2023
Raymond James Financial Services Advisors Inc. Sells 57417 ... - MarketBeat

Wed, 24 May 2023
Will 89bio Inc (ETNB) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 73 (M)
Shares Float 61 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 68.7 (%)
Shares Short 7,220 (K)
Shares Short P.Month 7,640 (K)

Stock Financials

EPS -2.3
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.11
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -21
Return on Equity (ttm) -38.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.45
Qtrly Earnings Growth 0
Operating Cash Flow -87 (M)
Levered Free Cash Flow -49 (M)

Stock Valuations

PE Ratio -8.84
PEG Ratio -0.9
Price to Book value 3.31
Price to Sales 0
Price to Cash Flow -17.05

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.